Group items tagged

To increase efficiency savings, digital men's health provider Numan has joined forces with Invatech Health to deploy the health tech company's cutting-edge software Titan. Launched in early 2019, Numan provides medication for 175,000 patients via its Cardiff-based fulfilment operation. A team of its clinicians create personalised treatment plans for the most common male health concerns. In a statement, Invatech said its Titan software could deliver 20 per cent efficiency savings for Numan whilst supporting the company's ambitious growth plans with improved safety and scalability in processing medications. The new partnership also comes alongside 100 new contracts with community pharmacies around the UK. Andrew Caple, director of Pharmacy Operations at of Numan, said: "Our findings show that three quarters of men will not visit a doctor when they have a health concern, and we therefore recognise that the online market provides a great opportunity to tackle these problems.

The strength of any organisation lies in its people. This being a common norm in the world of business, several of them are taking healthy initiatives and opening discussions around gender diversity and equality. Panelists during a session on Empowering Women In the Workplace held during the Pharmacy Business Diversity Conference on Thursday (December 9), agreed that having gender diversity in business, not just benefits women, but the whole organisation. "It drives engagement, diversity of thinking and ultimately performance," said Ifti Khan, pharmacy superintendent at Well Pharmacy, in the session moderated by the conference chair and BBC presenter Clive Myrie. To substantiate his point, he cited a recent report by McKinsey & Company, as per which companies in the top quartile for ethnic and cultural diversity are 36 per cent more profitable than those in the fourth quartile.

The NHS is on track to miss out on savings of over a billion pounds as patents for a new lineup of 85 biologics are set to expire within the next five years, the British Generic Manufacturers Association has revealed in its new study. The government's Voluntary Scheme for Branded Medicines Pricing and Access is expected to lead to a cost of more than £1 billion for the NHS in the coming years. The BGMA research found that more than 85 biological medicines will experience loss of exclusivity during the upcoming VPAS Scheme period from 2024 to 2028. "This includes blockbuster products like the cancer medicine Keytruda and wet macular product Eylea, which together generate approximately $25 billion in global sales," BGMA said. "The molecules coming off-patent also cover other disease areas including oncology, diabetes, arthritis, and asthma." While biological medicines dominate the medicines budget, constituting the largest cost and cost growth sectors, NHS England aims to expedite biosimilar availability, yielding substantial savings and expanding patient access to vital treatments. Yet, the report found that "this is jeopardised by the influence of the VPAS Scheme".

Day Lewis Pharmacy has enlisted Locate a Locum, a Belfast-based healthcare technology innovator, to deploy and manage a digital solution aimed at enhancing locum staffing and management across its 267-pharmacy network. "We sought a faster, user-friendly system for instant locum bookings, particularly for last-minute shifts," said Sam Patel, Executive Director at Day Lewis Pharmacy. "This tool improves communication between potential locums and our coordinators, creating more opportunities to attract talent from across the country. Our customers are our priority, and ensuring they have access to staff and advice when needed is our main focus." Locate a Locum will implement a cloud-based digital solution across the Day Lewis Pharmacy estate, allowing locums to securely search, manage, request, and receive payment for shifts, Day Lewis said in a statement. This platform enables locum staff to manage their work diaries, location preferences, and commitments, promoting balanced work-life planning. "The Locate a Locum platform allows for swift, complete payments to our locums and offers them instant booking, eliminating the need for shift confirmation wait times," Patel added. "In a dynamic market with rising demand for pharmacy services, this platform is a game-changer, driving growth and unlocking potential."

Skelmersdale-based online pharmacy Chemist4U has secured a £12 million investment from Pitalia Capital, an equity investment company led by Anil Pitalia. Chemist4U is part of JCCO Healthcare, which also houses the weight management platform myBMI. Anil Pitalia is a health enthusiast, who heads SpaMedica, a company providing cataract surgery to the NHS. This investment will propel the group's expansion, with John Davies, Managing Partner of Pitalia Capital, joining the board, the company said. Moreover, it will facilitate the extension of services by myBMI in the realm of weight management. "Our goal is for Chemist4U to emerge as one of the largest NHS dispensing facilities in the country, while also providing vital support to our partners through our rapidly expanding outsourced dispensing services division," said said James O'Loan, Chief Executive Officer of both Chemist4U and myBMI, who joined Chemist4U as a superintendent pharmacist in 2012 before becoming CEO in 2018. Meanwhile, Anil Pitalia, Head of Pitalia Capital based in Bolton, cited the compelling growth potential as the driving force behind his investment in Chemist4U's next-day medicine delivery service.

The Association of Pharmacy Technicians UK (APTUK) has urged the General Pharmaceutical Council (GPhC) to collate the data on actively enrolled on an approved course or qualification for Pharmacy Technicians of commencement of training. In a letter from Nicola Stockmann, Vice President APTUK to the GPhC to encourage the collection of data for Pre-Registration Training Pharmacy Technicians, Stockmann said: "We value the GPHC data for Pharmacy Technician registrants to track the growth and diversity of the Pharmacy Technician profession. With ongoing inclusive pharmacy practice priorities, APTUK has an organisational pledge to continue this work of all themes through actions. The demographics of the Pharmacy Technician workforce continue to have a majority of white British registrants and identifying as female; the high-level data collated which is currently available on the GPHC website does not capture those who are actively enrolled on an approved course or qualification for Pharmacy Technicians."

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."

Restricting sales of vape products to pharmacies is not a solution to curb illegal sales of vape among underage adults, said UK Vaping Industry Association (UKVIA). In an oral evidence at the House of Commons on 'Youth Vaping' called by the Health and Social Care Select Committee (HSSC) to figure out action needed to reduce vaping among those under 18. Rachael Maskell, York Central MP's suggested on vape products being available from licensed pharmacies. Marcus Saxton, Chairman, Independent British Vape Trade Association (IBVTA) said: "We are calling for further regulation to tighten up what has now been an extreme growth in single-use products. If you put them into those environments, as New Zealand and Australia are telling us, the perception of the public is that, while they can buy tobacco freely anywhere, the vaping product that is up to 95% safer is licensed through a pharmacy. It makes absolutely no sense. The negative consequence of considering such a thing will take us backwards years."

Despite significant sales growth in the quarterly results, high street chemist Boots is moving forward with its plan to close 300 stores in the UK. The move, aimed at improving profit margins amid rising costs and competition, will reduce the chain's portfolio from around 2,200 to just 1,900. Last month, the U.S.-based Walgreens Boots Alliance, the parent company of Boots, announced upcoming store closures within the next year. However, the company assured that there will be no job losses as all employees will be given the opportunity to be redeployed to nearby shops. The following sites are confirmed for closure on the specified dates: Heathside Rd, Woking (end of July) UEA campus (end of July) Hamlet Ct Rd, Westcliff-on-Sea (August 1) Windhill Road, Wakefield (October 6) Upper Warrengate, Wakefield (October 7) Glastonbury (October 13) Guildford Road, Woking (end of October) Boots stores at Salford Shopping Centre in Greater Manchester, Church Street in Malvern, The Port Arcades Shopping Centre in Ellesmere, and King William Street in London have already closed since spring.

Susan Rienow, UK Managing Director and Country President of Pfizer is all set to take up her role as President of the Association of the British Pharmaceutical Industry (ABPI). The association had announced her appointment in March. Last year in September she was appointed as the vice-president of ABPI. In her new role, she will oversee the ABPI, the ABPI Board, and the ABPI's Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA). Susan takes up the Presidency as negotiations begin for a new Voluntary Scheme for branded medicines pricing between the government, NHS England and the ABPI. All parties are looking to secure a new agreement that will help improve patient outcomes, support a healthier population and a financially sustainable NHS, while also supporting economic growth for the UK.

In a rapidly evolving and competitive landscape, the pharmaceutical industry faces unique challenges when it comes to marketing its products and services. With stringent regulations, complex target audiences, and a need for trust and credibility, pharma companies need to employ effective marketing strategies to stand out in the crowd. In this blog article, we will explore some key marketing strategies for the pharma industry that can help boost their visibility, engage their target audience, and drive business growth. UNDERSTANDING THE UNIQUE LANDSCAPE The pharma industry operates in a highly regulated environment, where compliance and ethical considerations play a crucial role. Before diving into marketing strategies, it is essential to have a deep understanding of the industry's dynamics and the target audience. Researching the market, identifying patient needs, and studying the competitive landscape are vital steps in developing an effective marketing plan. EMBRACING DIGITAL TRANSFORMATION Digital transformation has revolutionized marketing across industries, and the pharma sector is no exception. Embracing digital channels and technologies can significantly enhance the reach and impact of marketing efforts. Pharma companies can leverage social media platforms, create engaging content, and build online communities to connect with patients, healthcare professionals, and other stakeholders. Implementing robust digital marketing strategies allows for personalized messaging, real-time communication, and targeted campaigns that resonate with the target audience.

Pharmacist Support, a charity centred on bolstering pharmacist well-being, has launched the 'ACTNow' campaign 2023, aimed at promoting and supporting the health and overall wellbeing of pharmacists. This campaign is launched following the successful 2022 initiative, which heightened awareness about wellbeing in the pharmacy profession. Launched in May 2020 in response to COVID-19 challenges, ACTNow has transformed into a dynamic platform fostering positive workplace culture, teamwork, and individual well-being, Pharmacist Support has said. Its primary goals are to inspire individuals and teams in the profession to prioritise their well-being, support colleagues, and proactively foster a healthier work environment. Pharmacist Support emphasised that the 2023 ACTNow campaign will continue to prioritise fostering a positive workplace culture. "This year, the campaign will provide individuals, pharmacy teams, and employers with essential tools, resources, and strategies to effectively support colleagues dealing with distress, all while cultivating a growth-oriented mindset within their teams," the charity firm said.

AAH Pharmaceuticals on Tuesday (November 15) announced the promotion of its commercial director David Bound to chief executive officer of the company. In his 10 years in the company, Mr Bound has helped to drive growth across the AAH business, implementing new digital channels for customers, and developing strategic partnerships with pharmaceutical manufacturers - drawing on from his vast experience in the healthcare industry, as well as in supply chain, operations, and trading. Commenting on his promotion, he said: "I'm delighted to be taking on this role at such a critical time for healthcare. There are many challenges affecting the industry right now - from inflationary pressures to workforce issues - and I'm looking forward to tackling them head-on alongside my excellent team."

Despite a 13 per cent increase from last year, less than a quarter (21%) of pharmacy teams recommend Proton Pump Inhibitors (PPIs) as a first line of treatment for frequent heartburn. There has been a 4% decrease in pharmacy teams considering 'frequent heartburn' as a condition that occurs more than once a week 8-in-10 said a larger pack size would be useful to their patients who suffer from frequent heartburn. Haleon, formerly part of GSK, has recently commissioned research to better understand how pharmacy teams help patients to treat frequent heartburn. Comparing with data captured last year, there has been a been a +13% increase in the number of pharmacy teams recommending Proton Pump Inhibitors (PPIs) (21% in 2022 vs 8% in 2021). Nexium Control, the UK's number one heartburn product for 24-hour protection, aims to use this research to provide better support for pharmacists and their teams and encourage the recommendation of PPIs, where appropriate for frequent heartburn, over other heartburn remedies.

AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and purpose-driven approach to creating healthier futures. Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care." AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.

Danish drug developer Novo Nordisk on Wednesday (February 1) warned of supply constraints on its best-selling drug. The company, which develops diabetes and obesity drugs, said it expected "periodic supply constraints" this year, partly driven by higher than expected demand for its blockbuster diabetes drug, Ozempic, and manufacturing constraints. "Supply of Ozempic cannot keep up with demand in some markets," Novo's Chief Financial Officer Karsten Munk Knudsen told journalists on Wednesday, but said Ozempic was available in the United States, the firm's biggest single market. Shortages of human growth hormone would also cause sales in its rare disease franchise to drop by a "mid-single digit" percentage in 2023, as its Norditropin drug would be out of stock in certain markets, Knudsen said.

Novartis on Wednesday (February 1) predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4 per cent to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya. Novartis said it was on track to spin off its generics unit Sandoz in the second half of the year as part of its effort to sharpen its focus on its patented prescription medicines. Analysts have welcomed a programme unveiled in 2022 to trim costs and cut 8,000 jobs and plans to focus on fewer therapy areas and drug technologies. But the market has been underwhelmed by prospects for medium-term growth from new drugs.

The UK Health Security Agency (UKHSA) said last week (Aug 5) there were "early signs" that the monkeypox outbreak was plateauing across the country and that its expansion had slowed. "While the most recent data suggests the growth of the outbreak has slowed, we cannot be complacent," Dr Meera Chand, director of clinical and emerging infections at UKHSA, said. There were 2,859 confirmed and highly probable cases of monkeypox in the UK as of Aug. 4, with nearly 99 per cent of the cases among men, the country's health authority said in a statement. The recent analysis by the UKHSA showed that "monkeypox continues to be transmitted primarily in interconnected sexual networks of gay, bisexual, or other men who have sex with men", it added. British authorities in June were recommending gay and bisexual men at higher risk of exposure to monkeypox be offered a vaccine, as the outbreak of the viral disease had gathered pace, mostly in Europe.

HRA pharma has announced the resignation of David Wright who moves on after serving the company for more than five years as chief executive officer. The company has appointed Martyn Hilton, chief commercial officer for HRA Pharma, as interim CEO effective from September 1, 2022. David helmed the company during a period of transformation and set the course for its tremendous growth, elevating HRA Pharma into a leading provider of over-the-counter self-care products. He commented: "Given the significant progress HRA has made, along with my personal goals after leading HRA for more than five years, I believe now is the time to step away from the business. "I am proud of all that we have accomplished, making HRA well-known for its Women's Health, Wound Care and Scar Care leadership, operating via brands including ellaOne, Hana, Compeed and Mederma. I appreciate all the team members involved in the success of the organization and believe Perrigo and HRA are well-positioned to elevate this business and these brands to the next level."

Supplements became hugely popular in the last decade to treat deficiencies and boost various body functions. People who work out use supplements to promote muscle growth and gain energy during exercise. If you are suffering from hormone or vitamin deficiency, you can get off-the-shelf supplements to get your daily intake of these vitamins. However, there have been cases where some people became too reliant on supplements and started taking more than the required dose. Although most of them are made from natural ingredients, it's not particularly safe to use any supplement before understanding what it is and if you actually need it. Here are a few things you need to know before taking supplements or pill products. SUPPLEMENTS DON'T REPLACE A HEALTHY LIFESTYLE Taking supplements every day doesn't mean you are leading a healthy lifestyle. Supplements support this lifestyle but they're not the basis of being healthy. If someone doesn't exercise, eats junk food all the time, and smokes heavily, taking supplements will not make them live or feel better. It all starts with leading a healthy lifestyle, and if you want to boost body function or treat a deficiency, then supplements will have the desired effect. EVERYONE IS DIFFERENT There is no magic solution that works for everyone on the planet. What worked for your friend may not necessarily work for you. Popping a pill or drinking a supplement shake won't improve your performance unless you are taking the right supplement for what you need to be targeted. For instance, vitamin B12 comes from meat, fish, and dairy foods, so vegans should look for a supplement that will provide them with this vitamin.